Your browser doesn't support javascript.
loading
The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management.
Marchi, Enrica; O'Connor, Owen A.
Afiliação
  • Marchi E; Department of Medicine, Center for Lymphoid Malignancies, Columbia University Medical Center, College of Physicians and Surgeons, New York, New York.
  • O'Connor OA; Department of Medicine, Center for Lymphoid Malignancies, Columbia University Medical Center, College of Physicians and Surgeons, New York, New York.
CA Cancer J Clin ; 70(1): 47-70, 2020 01.
Article em En | MEDLINE | ID: mdl-31815293
Historical advances in the care of patients with non-Hodgkin lymphoma (NHL) have been restricted largely to patients with B-cell lymphoma. The peripheral T-cell lymphomas (PTCLs), which are rare and heterogeneous in nature, have yet to experience the same degree of improvement in outcome over the past 20 to 30 years. It is estimated that there are approximately 80,000 and 14,000 cases, respectively, of NHL and Hodgkin lymphoma per year in the United States. As a subgroup of NHL, the PTCLs account for 6% to 10% of all cases of NHL, making them exceedingly rare. In addition, the World Health Organization 2017 classification describes 29 distinct subtypes of PTCL. This intrinsic diversity, coupled with its rarity, has stymied progress in the disease. In addition, most subtypes carry an inferior prognosis compared with their B-cell counterparts, an outcome largely attributed to the fact that most treatment paradigms for patients with PTCL have been derived from B-cell neoplasms, a radically different disease. In fact, the first drug ever approved for patients with PTCL was approved only a decade ago. The plethora of recent drug approvals in PTCL, coupled with a deeper understanding of the molecular pathogenesis of the disease, has stimulated the field to pursue new avenues of research that are now largely predicated on the development of novel, targeted small molecules, which include a host of epigenetic modifiers and biologics. There is an expectation these advances may begin to favorably challenge the chemotherapy paradigms that have been used in the T-cell malignancies.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Linfoma de Células T Periférico / Estadiamento de Neoplasias / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: CA Cancer J Clin Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Linfoma de Células T Periférico / Estadiamento de Neoplasias / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: CA Cancer J Clin Ano de publicação: 2020 Tipo de documento: Article